Insider · CIK 0001707715
David Scadden
Files at AGIO (AGIOS PHARMACEUTICALS, INC.). First filing Dec 13, 2024, latest Dec 13, 2024.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
AGIO: AGIOS PHARMACEUTICALS, INC.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 0Weak | AGIOS PHARMACEUTICALS, INC. | $9,256 200 shares | -1% | - |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 20, 2025 | AGIO AGIOS PHARMACEUTICALS, INC. | MOption exercise Common stock | +2,120 | $0.00 | $0 | 17,603 | Jun 23, 2025 |
| Jun 18, 2025 | AGIO AGIOS PHARMACEUTICALS, INC. | AGrant or award Restricted stock unitsderivative | +2,816 | $0.00 | $0 | 2,816 | Jun 23, 2025 |
| Jun 18, 2025 | AGIO AGIOS PHARMACEUTICALS, INC. | AGrant or award Stock options (right to buy)derivative | +15,768 | $0.00 | $0 | 15,768 | Jun 23, 2025 |
| Jun 20, 2025 | AGIO AGIOS PHARMACEUTICALS, INC. | MOption exercise Restricted stock unitsderivative | -2,120 | $0.00 | $0 | 0 | Jun 23, 2025 |
| Dec 11, 2024 | AGIO AGIOS PHARMACEUTICALS, INC. | MOption exercise Common stock10b5-1 | +200 | $18.09 | $3,618 | 15,683 | Dec 13, 2024 |
| Dec 11, 2024 | AGIO AGIOS PHARMACEUTICALS, INC. | SOpen-market sale Common stock10b5-1 | -200 | $46.28 | $9,256 | 15,483 | Dec 13, 2024 |
| Dec 11, 2024 | AGIO AGIOS PHARMACEUTICALS, INC. | MOption exercise Stock options (right to buy)derivative10b5-1 | -200 | $0.00 | $0 | 29,107 | Dec 13, 2024 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.